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CASE STUDY
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mebutate 0.015 % gel: a single center case 
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Abstract 
Introduction: Actinic keratosis (AK) is a cutaneous intraepithelial neoplasm appearing within areas referred as ‘fields 
of cancerization’. AK can progress to invasive squamous cell carcinoma. Treatments that target both clinically visible 
and subclinical AKs in cancerization fields are able to reduce the risk of malignant progression. Ingenol mebutate gel 
is a new effective topical therapy for AK, used once daily for 2 or 3 days depending on the location of lesions.
Case description: Three elderly patients with multiple non-hypertrophic AKs within a contiguous 25-cm2 treatment 
area on the face or scalp were treated with ingenol mebutate 0.015 % gel once daily for three consecutive days and 
followed up over a period of 57 days.
Discussion and Evaluation: Although individual local responses to treatment varied, all patients had total clearance 
of AK lesions without any sign of recurrence. In addition, all patients said that they were satisfied with the effective-
ness of ingenol mebutate treatment and the aesthetic outcome, and would be prepared to use this agent again to 
treat AK in the future, if necessary.
Conclusions: These three cases demonstrate that ingenol mebutate 0.015 % gel is effective and well tolerated in a 
clinical setting, with effective clearance of AK lesions present on the face and scalp, and good patient acceptability.
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Background
Actinic keratosis (AK) is a cutaneous intraepithelial 
neoplasm [early-stage squamous cell carcinoma (SCC)] 
that is relatively common in elderly individuals with 
sun-damaged skin. AK is the most common cutaneous 
lesion encountered in clinical practice and its incidence 
is increasing worldwide (Ortonne 2002). There are a 
number of reasons for this, including the thinning of the 
ozone layer (which results in more ultraviolet radiation 
reaching earth) and lifestyle factors (such as the desire to 
achieve tanned skin) (Chetty et al. 2015).
Characteristic features of AK include keratotic mac-
ules, papules, or plaques with superficial scales on a red 
background, which are classified as hypertrophic, bowe-
noid, atrophic, acantholytic, epidermolytic, lichenoid 
and/or pigmented based on histological features. AK 
lesions may be sore or itchy but many patients experience 
no symptoms at all (Moy 2000).
A dermoscopic classification, useful for diagnosis of 
pigmented and non-pigmented skin lesions, has recently 
been proposed that recognizes 3 different grades of classi-
cal non-pigmented AK (Grade 1, 2, or 3), plus pigmented 
and lichenoid AK (Zalaudek and Argenziano 2015). Grade 
1 refers to lesions that are slightly palpable and better felt 
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than seen, Grade 2 to many visible, small, moderately 
thick or a few large, thick, rough scaly lesions, and Grade 
3 to many thick, hyperkeratotic lesions that are clearly vis-
ible and palpable with well-defined borders. Furthermore, 
AKs show increased vascularization (neo-angiogenesis) 
and have higher capillary densities than surrounding nor-
mal tissue, both of which become more severe and evi-
dent in invasive skin lesions (Cantisani et al. 2015).
If left untreated, some AK lesions have the potential 
to progress to invasive SCC (iSCC); data suggest that 
72–82.4 % of identified SCCs arise contiguously with, or 
within and/or in close proximity to, AKs (Czarnecki et al. 
2002). While there is no way of predicting exactly which 
individual AK lesions will progress into iSCC, the risk 
of such progression has been estimated to be 0.6 % over 
1  year and 2.57  % over 4  years (Werner et  al. 2013). In 
the absence of reliable ways to predict progression of AK 
lesions to iSCC, treatment of the ‘field of cancerization’ 
is an important aspect of AK treatment. This term was 
originally used by Slaughter et al. in 1953 to refer to his-
tologically abnormal epithelium adjacent to tumor tissue 
and was designed to explain the occurrence of multiple 
primary tumors as well as locally recurrent cancer (Kauf-
man 2010; Slaughter et al. 1953).
There are a number of options available for the manage-
ment of AKs. The specific choice of approach depends on 
a number of factors, including lesion distribution, num-
ber and thickness, as well as previous treatments and epi-
sodes of recurrence. Options directly targeting the lesion 
include cryotherapy, laser therapy, curettage and derma-
brasion; field-directed therapies are imiquimod, photody-
namic therapy (PDT) and ingenol mebutate (Goldenberg 
and Perl 2014). Field-directed therapies have the ability to 
target both clinically visible and subclinical AKs in a can-
cerization field, meaning that they have a greater potential 
to reduce the risk of malignant progression.
Ingenol mebutate is a diterpene ester derived from the 
sap of the Euphorbia peplus (petty spurge) plant. Topi-
cal application is associated with both chemo-ablative 
and immunomodulatory effects (Dodds et  al. 2014). This 
combination of activity results in preferential cell death in 
transformed keratinocytes and an inflammatory reaction 
that kills any remaining cancerous cells (Martin and Swan-
son 2013). However, the precise mechanism of action of 
ingenol mebutate is still the subject of research. A recent 
study suggested that ingenol mebutate-induced cell death is 
mediated through the PKCδ/MEK/ERK pathway, and that 
downstream induction of IL1R2 and IL13RA2 expression 
reduce the viability of treated cells (Freiberger et al. 2015).
This series of cases provides treatment and follow-up 
data on the efficacy, safety and tolerability of ingenol 
mebutate 0.015 % gel for the treatment of AKs on the face 
or scalp.
Case presentation
We present details for 3 elderly patients with multiple 
(>6) lesions non-hypertrophic AK lesions within a con-
tiguous 25-cm2 treatment area on the face or scalp. All 
patients were treated with ingenol mebutate 0.015 % gel 
once daily for three consecutive days, then assessed after 
4  days for evaluation of local skin response (LSR) and 
recording of adverse events. A third assessment was per-
formed after 15 days to evaluate the LSR, treatment effi-
cacy [defined as total clearance (complete disappearance 
of all the lesions) or partial clearance (75 % reduction in 
the number of lesions) in the treated area], and adverse 
events. The final evaluation at 57 days assessed the LSR 
and definitive treatment results (total or partial clear-
ance), adverse events (appearance of scars, hyperpigmen-
tation, hypopigmentation), patient satisfaction [rated on 
a visual analogue scale (VAS) from 0 (extremely dissatis-
fied) to 10 (extremely satisfied)], and any requirement for 
retreatment.
All patients were given verbal and written informa-
tion about the treatment procedures, LSR and possible 
treatment-related side effects. Written informed consent 
was obtained from all participants in accordance with the 
latest revision of the Declaration of Helsinki (2009/58). 
Patients provided consent to the publication of their case 
details and the related images.
Case 1
A 78-year-old man presented to the clinic with a 3-year 
history of multiple erythematous, scaly macules and 
papules on a red base located on the frontal region. The 
patient also reported a history of relapsing, remitting 
lesions a few months after multiple cryotherapy ses-
sions. Physical examination showed multiple rough, 
dry, erythematous, scaly and raised bumps and patches 
that were 0.5–1.0  cm in size (Fig.  1a). Dermoscopic 
examination revealed the presence of hair follicle 
openings filled with yellowish keratotic plugs and sur-
rounded by a white halo with a targetoid-like appear-
ance on a red background (“strawberry pattern”). The 
patient was treated with ingenol mebutate 0.015 % gel 
on the right frontal 25-cm2 treatment area for 3 con-
secutive days. LSR on day 4 was severe (Fig.  1b), with 
edema, erythema, confluent pustules, erosions, severe 
crusts and periorbital edema, but no additional treat-
ment was required and the patient’s adherence to 
treatment was not affected. The LSR had resolved com-
pletely after 15  days without scars (Campanati et  al. 
2010) or skin color change, and healthy skin with com-
plete AK clearance was achieved (Fig. 1c). Most of the 
dermoscopic features of AKs disappeared after ingenol 
mebutate treatment. Total clearance of AK lesions was 
observed after 57 days of follow-up without any sign of 
Page 3 of 6Bobyr et al. SpringerPlus  (2016) 5:627 
recurrence (Fig.  1d). The patient reported that he was 
satisfied (VAS score = 9) with the effectiveness of treat-
ment and the aesthetic outcome, and said he would be 
prepared to use the same treatment again in future, if 
necessary.
Case 2
An elderly woman (age 73 years) with a 4-year history of 
multiple discrete non-hypertrophic and pigmented AKs 
within the frontal region presented for treatment. Physi-
cal examination showed multiple erythematous macules, 
scaly and raised bumps, and brown patches (0.3–1.2 cm 
in size) on sun-damaged skin (Fig.  2a). Annular–granu-
lar structures characterized by the coalescence of small, 
grey to brown dots and globules around hair follicles and 
typical brown pseudo-network were evident on dermos-
copy. Treatment with ingenol mebutate 0.015  % gel was 
prescribed, which the patient applied to the left frontal 
25-cm2 treatment area for 3 consecutive days. LSR on day 
4 was moderate (Fig.  2b), with edema, erythema, some 
pustules, mild erosion and a few crusts. The patient did 
not need any additional treatment and there was complete 
resolution of LSR after 15 days without sequelae, and skin 
photorejuvenation with complete AK lesion clearance was 
observed (Fig.  2c). Most of the initial dermoscopic fea-
tures of AK lesions had disappeared on reassessment after 
treatment. At 57 days’ follow-up, there was total clearance 
of AK lesions without signs of recurrence (Fig.  2d). The 
patient was very satisfied with the clinical and aesthetic 
outcomes of treatment (VAS score = 10) and stated her 
willingness to undergo another ingenol mebutate treat-
ment course if necessary in the future.
Case 3
A 62-year-old male with fair skin presented with multiple 
erythematous, scaly macules and papules on the fronto-
parietal scalp area that had been present for 2  years. He 
did not report any soreness or itch. Physical examination 
showed multiple, moderately thick erythematous scaly 
lesions and other signs of solar damage, such as solar 
elastosis (Fig.  3a). Dermoscopic examination revealed 
the presence of unfocussed large caliber vessels located 
between the hair follicles and arranged in a reddish 
pseudo-network with discrete white scale. Treatment with 
ingenol mebutate 0.015 % gel for 3 consecutive days was 
prescribed and the patient was instructed to apply this to 
a 25-cm2 treatment area on the vertex for 3 consecutive 
days. LSR on day 4 was mild (Fig. 3b), with application-site 
pruritus, very mild erythema, few pustules, some scales 
and crusts. The patient did not experience any LSR-related 
symptoms and did not require any additional treatment. 
Crusts persisted for the following 2 weeks (Fig. 3c), but all 
had disappeared within another week after that. Complete 
resolution of LSR was evident after 22 days, without scars, 
hyperpigmentation, hypopigmentation, and complete AK 
lesion clearance was obtained. Most of the dermoscopic 
features of AK disappeared after ingenol mebutate treat-
ment. There was total clearance of AK lesions after 57 days 
Fig. 1 a Clinical presentation at base-line; b LSR on day 4; c 15 days 
of follow-up; d 57 days of follow-up
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and no signs of recurrence (Fig. 3d). This patient was also 
satisfied with the clinical results associated with ingenol 
mebutato (VAS score  =  10) and said he would use the 
treatment again in the future if he needed to.
Discussion
There are a number of field therapies available for the 
treatment of AK, including imiquimod 5  %, 5-fluoro-
uracil (5-FU), diclofenac 5 %, hyaluronic acid 2.5 %, and 
PDT (Dodds et al. 2014). The usefulness of some agents 
is limited by a need for prolonged use and the occur-
rence of associated inflammatory effects, which decrease 
the tolerability and acceptability of treatment, which in 
turn could reduce patient adherence (Shergill et al. 2013). 
On that basis, the ideal treatment for AK in the clinical 
setting would be one that is easy and convenient to use, 
provides good and sustained clearance of AK lesions, 
reduces the risk of malignant transformation, and is well 
tolerated (Garbe et al. 2016).
Data from a number of clinical studies suggest that 
ingenol mebutate is an effective and well tolerated field-
directed treatment for AK (Garbe et  al. 2016; Lebwohl 
et  al. 2012, 2013). Furthermore, the findings of a meta-
analysis comparing different treatments for AK of the face 
or scalp showed that clearance rates with ingenol mebu-
tate were similar to those of imiquimod 5 % and 5-FU for 
4 weeks, and were superior to those of diclofenac, imiqui-
mod 3.75  % and cryotherapy (Vegter and Tolley 2014). 
LSRs (including erythema, edema, scaling, crusting, swell-
ing, vesiculation and pustulation, erosion or superficial 
ulceration at the application site) are the most common 
Fig. 2 a Clinical presentation at base-line; b LSR on day 4; c 15 days 
of follow-up; d 57 days of follow-up
Fig. 3 a Clinical presentation at base-line; b LSR on day 4; c 15 days 
of follow-up; d 57 days of follow-up
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side effects of ingenol mebutate, but usually resolve spon-
taneously within 2 weeks. Transient application-site pain 
and itch are the most commonly reported ingenol meb-
utate-induced adverse events (AEs) (Rosen et  al. 2014). 
Data from a recent prospective, randomized study indi-
cated that although the peak intensity of LSR was similar 
for ingenol mebutate 0.015 % gel and 5-FU 5 %, the area 
under the curve for LSRs and pain was significantly lower 
with ingenol mebutate (Samorano et al. 2015).
The outcomes in our three patients are consistent 
with currently available data for ingenol mebutate in 
AK, which show sustained lesion reduction, clinically-
relevant clearance and reduced numbers of lesions in the 
treated field. In addition, our use of ingenol mebutate in 
clinical practice confirmed that this agent is well toler-
ated, with a safety profile comparable to that in previous 
studies. The LSRs experienced by our treated patients 
were mild to moderate and all resolved without seque-
lae within 2  weeks of treatment initiation. None of the 
patients needed any additional treatment and LSRs did 
not influence their adherence to treatment. In addition, 
all three patients were satisfied with the clinical efficacy 
and aesthetic outcome of ingenol mebutate treatment 
and said they would be willing to use the drug again in 
the future if necessary.
Conclusions
These three cases demonstrate the efficacious and safe 
use of ingenol mebutate 0.015 % gel in a clinical setting, 
with effective clearance of AK lesions present on the face 
and scalp. Our experiences adds to data showing that 
ingenol mebutate can be used for field treatment of AK, 
demonstrating an acceptable safety profile and a high sus-
tained clearance rate. The benefits of ingenol mebutate in 
this setting include the short duration of treatment, ease 
of self-application, transient, self-limiting adverse effects, 
and an improvement in skin quality.
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